Hypolipidemic effect of beta, beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats
| Autor: | Baruch Frenkel, M Fainaru, G Rose-Kahn, Jacob Bar-Tana, Z Shafer |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
medicine.medical_specialty
Very low-density lipoprotein Cholesterol nutritional and metabolic diseases QD415-436 Cell Biology digestive system Biochemistry chemistry.chemical_compound Endocrinology chemistry Puromycin Internal medicine Concomitant Lipogenesis Hypolipidemic Agents medicine Hexadecanedioic acid lipids (amino acids peptides and proteins) Beta (finance) |
| Zdroj: | Journal of Lipid Research, Vol 29, Iss 4, Pp 431-441 (1988) |
| ISSN: | 0022-2275 |
| Popis: | Treatment of normal or puromycin aminonucleoside-nephrotic rats, kept on a balanced Purina chow diet, with beta, beta'-tetramethyl-substituted hexadecanedioic acid (MEDICA 16) (Bar-Tana, J., G. Rose-Kahn, and M. Srebnik. 1985. J. Biol. Chem. 260: 8404-8410) resulted in an acute reversible inhibition of liver lipogenesis and cholesterogenesis with a concomitant hypolipidemic effect which was sustained as long as the drug was administered. The hypolipidemic effect in normal and nephrotic rats consisted of 70-80% and 40-60% reduction in plasma VLDL-triacylglycerols and cholesterol, respectively, with a respective increase in the HDL-cholesterol/(VLDL + LDL)-cholesterol ratio. The observed hypolipidemic effect was accompanied by a 10-fold decrease in VLDL-apoC-III content with a concomitant enrichment of the VLDL fraction by VLDL remnants having an increased apoB-100/apoB-48 ratio. The pharmacological reduction of VLDL by MEDICA 16 may offer a treatment mode of choice for selected hyperlipidemic states. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|